TD Cowen Issues Positive Forecast for Agilent Technologies (NYSE:A) Stock Price

Key Points

• TD Cowen raised its price target on Agilent Technologies from $147 to $155 and kept a buy rating, implying about 14.5% upside from the current share price.
• Agilent’s latest quarterly results beat expectations, with EPS of $1.49 and revenue of $1.84 billion, while revenue rose 10% year over year.
• The company also lifted its full-year 2026 guidance, and the article notes broader analyst sentiment remains positive with a consensus Buy rating and average price target of about $160.93.

Agilent Technologies (NYSE:A - Get Free Report) had its price objective raised by equities researchers at TD Cowen from $147.00 to $155.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the medical research company's stock. TD Cowen's price target indicates a potential upside of 14.52% from the company's current price.

Several other research firms have also commented on A. Bank of America raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $150.00 to $145.00 in a research note on Thursday. Wells Fargo & Company dropped their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research note on Thursday. Robert W. Baird lifted their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the stock an "outperform" rating in a research note on Tuesday. Wall Street Zen lowered shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Morgan Stanley dropped their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Agilent Technologies presently has an average rating of "Buy" and a consensus price target of $160.93.

Agilent Technologies Trading Up 16.8%

NYSE A traded up $19.50 on Thursday, hitting $135.34. 2,216,560 shares of the stock were exchanged, compared to its average volume of 2,189,931. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07. The stock has a fifty day moving average price of $114.99 and a two-hundred day moving average price of $128.79. The firm has a market capitalization of $38.25 billion, a P/E ratio of 29.67, a P/E/G ratio of 2.42 and a beta of 1.22. Agilent Technologies has a 52-week low of $108.35 and a 52-week high of $160.27.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. The company had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. Agilent Technologies's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Research analysts forecast that Agilent Technologies will post 5.95 EPS for the current fiscal year.

Institutional Trading of Agilent Technologies

A number of large investors have recently made changes to their positions in A. Bridgefront Capital LLC acquired a new stake in shares of Agilent Technologies during the 3rd quarter worth approximately $1,323,000. Wellington Management Group LLP grew its stake in shares of Agilent Technologies by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company's stock worth $1,203,990,000 after purchasing an additional 433,342 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Agilent Technologies by 3.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 607,914 shares of the medical research company's stock worth $78,026,000 after purchasing an additional 22,498 shares during the period. Generation Investment Management LLP lifted its position in shares of Agilent Technologies by 10.1% during the 3rd quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company's stock valued at $816,043,000 after buying an additional 582,093 shares in the last quarter. Finally, Champlain Investment Partners LLC lifted its position in shares of Agilent Technologies by 33.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 895,770 shares of the medical research company's stock valued at $114,972,000 after buying an additional 223,750 shares in the last quarter.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent beat Wall Street’s Q2 expectations, reporting adjusted EPS of $1.49 versus estimates around $1.41 and revenue of $1.83 billion, above forecasts, with revenue up 10% year over year. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 profit outlook and also issued Q3 guidance that points to continued growth, reinforcing confidence in demand for its lab tools and diagnostic products. Agilent raises 2026 profit forecast on strong demand for lab tools
• Positive Sentiment: Bank of America upgraded Agilent from neutral to buy, which typically helps sentiment because it signals improved confidence in the stock’s upside. Benzinga report on Bank of America upgrade
• Positive Sentiment: RBC also initiated coverage with an outperform rating and a $153 price target, adding another bullish analyst call after earnings. Benzinga report on RBC coverage
• Neutral Sentiment: Agilent also highlighted new product launches and digital-lab tools, including OpenLab Sync and new GC systems, which support the longer-term growth story but are less likely to move the stock immediately. Agilent Introduces OpenLab Sync

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.